History

Formac is a spin-off company from the University of Leuven, Belgium (K.U.Leuven), from which it has obtained the exclusive and worldwide rights to develop and commercialise ordered mesoporous silica materials for the delivery of poorly soluble API's.  The company was incorporated on 3 October 2007 and is privately owned. The main shareholders of Formac are K.U.Leuven, Allegro Investment Fund, Hunza Ventures, Gemma Frisius Fonds K.U.Leuven, Vinnof PMV and Life Sciences Research Partners VZW (formerly D. Collen Foundation).

Since its incorporation  Formac has signed more than 40 feasibility agreements with Tier 1 Pharma companies and SMEs in the field of human and veterinary medicine. To date, Formac is the only company that demonstrated the clinical relevancy of the silica based technology in a clinical setting.